Australia Cell And Gene Therapy Manufacturing Market Size & Outlook

The cell and gene therapy manufacturing market in Australia is expected to reach a projected revenue of US$ 1,050.2 million by 2030. A compound annual growth rate of 26% is expected of Australia cell and gene therapy manufacturing market from 2023 to 2030.
Revenue, 2022 (US$M)
$165.5
Forecast, 2030 (US$M)
$1,050.2
CAGR, 2023 - 2030
26%
Report Coverage
Australia

Australia cell and gene therapy manufacturing market, 2018-2030 (US$M)

Australia

Australia cell and gene therapy manufacturing market highlights

  • The Australia cell and gene therapy manufacturing market generated a revenue of USD 165.5 million in 2022 and is expected to reach USD 1,050.2 million by 2030.
  • The Australia market is expected to grow at a CAGR of 26% from 2023 to 2030.
  • In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
  • Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.


Cell and gene therapy manufacturing market data book summary

Market revenue in 2022USD 165.5 million
Market revenue in 2030USD 1,050.2 million
Growth rate26% (CAGR from 2022 to 2030)
Largest segmentCell therapy
Fastest growing segmentGene Therapy
Historical data2018 - 2021
Base year2022
Forecast period2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationGene Therapy, Cell Therapy
Key market players worldwideLonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd


Other key industry trends

  • In terms of revenue, Australia accounted for 2.3% of the global cell and gene therapy manufacturing market in 2022.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China cell and gene therapy manufacturing market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,689.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell And Gene Therapy Manufacturing Market Companies

Name Profile # Employees HQ Website

Australia cell and gene therapy manufacturing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.


Cell therapy was the largest segment with a revenue share of 67.92% in 2022. Horizon Databook has segmented the Australia cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.


With rising development efforts in Australia, the market is likely to witness increased demand for cell and gene therapies. For instance, in January 2022, the NSW government announced leveraging cell and gene therapy expertise to establish a commercial-scale viral vector manufacturing facility in the country.

Similarly, in May 2019, Therapeutic Innovation Australia (TIA) invested USD 8.8 million in cell and gene therapy facilities across Australia. Numerous clinical studies in cell and gene therapies are ongoing or have already been completed in the country, which has the potential to transform the treatment of various diseases, including cancer.

Moreover, announcements regarding reimbursement for Kymriah CAR-T therapy for acute lymphoblastic leukemia further emphasize the promising therapeutic potential of cell and gene therapies.

Reasons to subscribe to Australia cell and gene therapy manufacturing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Australia cell and gene therapy manufacturing market databook

  • Our clientele includes a mix of cell and gene therapy manufacturing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Australia cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Australia cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Australia cell and gene therapy manufacturing market size, by therapy type, 2018-2030 (US$M)

Australia Cell And Gene Therapy Manufacturing Market Outlook Share, 2022 & 2030 (US$M)

Australia cell and gene therapy manufacturing market size, by therapy type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more